⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27317105 | 0.53 | — | — | |
| SCHEMBL6713 | 0.53 | — | — | |
| SCHEMBL11330940 | 0.47 | — | — | |
| SCHEMBL16039847 | 0.47 | — | — | |
| Selenium SCHEMBL10893423 | 0.47 | — | — | |
| Fluoride SCHEMBL5033143 | 0.47 | — | — | |
| SCHEMBL11798212 | 0.47 | — | — | |
| Hydrogen Sulfide SCHEMBL10979966 | 0.47 | — | — | |
| Iodide SCHEMBL4433797 | 0.47 | — | — | |
| Ammonia Solution, Strong SCHEMBL8854726 | 0.47 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552826-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-02-17 | — | — | US | disclosed |
| US-12338262-B2 | Modulators of TNF-alpha activity | FORWARD THERAPEUTICS, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20240279258-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-11987597-B2 | Modulators of TNF-α activity | FORWARD THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240076306-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. | 2024-03-07 | — | — | US | disclosed |
| WO-2023240253-A2 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| EP-4285906-A2 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | Epizyme Inc (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230365526-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC (US) | 2023-11-16 | — | — | US | disclosed |
| EP-3555070-B1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | EPIZYME INC (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230027198-A1 | INHIBITORS OF ENL/AF9 YEATS | THE ROCKEFELLER UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| EP-4110771-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | Remix Therapeutics Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-4076440-A1 | INHIBITORS OF ENL/AF9 YEATS | The Rockefeller University (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021174170-A9 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| US-20220235065-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | Epizyme, Inc. | 2022-07-28 | — | — | US | disclosed |
| US-20210309687-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-10-07 | — | — | US | disclosed |
| WO-2021127166-A1 | INHIBITORS OF ENL/AF9 YEATS | THE ROCKEFELLER UNIVERSITY (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3833669-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-06-16 | — | — | EP | disclosed |
| WO-2020033285-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-13 | — | — | WO | disclosed |
| US-20200039998-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | Epizyme, Inc. | 2020-02-06 | — | — | US | disclosed |